Optimization and Characterization of Niosomal Transdermal Patch of Lornoxicam

Lornoxicam has a low solubility; therefore, its oral use is restricted due to its adverse effects on the gastric system. Hence, we intend to design a niosomal transdermal patch of Lornoxicam to improve clinical efficacy and enhance its absorption and penetration through the skin by applying surfactants. Surfactants generally improve the solubility and penetration of the active ingredients. The niosome vesicles are prepared by using the rotary film evaporation technique. The result showed that the percentage entrapment efficacy of unsonicated niosome vesicles was 70.13 ±0.2% and sonicated 72.39 ±0.02% of the optimized formulation. The sonicator apparatus reduced the size of vesicles; hence, the entrapment efficacy of sonicated formulations is greater than that of unsonicated formulations. The in vitro release of optimized niosomal patches formulations (TPF1- TPF2-TPF3) was performed for 6 hours across the egg membrane, where results showed that the maximum release of TPF1 formulation due to less thickness (121 ±1.53 μm) was 90.86%.